The resumption of operations at T2 will be with 96 air traffic movements (48 departures and 48 arrivals) per day and increase progressively up to 180 by October end, GMR Group says
Delhi NCR pollution level today: Air monitoring agency SFAR predicts favorable ventilation condition is likely to keep Delhi AQI in the moderate category for the next three days.
The CVC received a large number of complaints against public servants working in the state governments and other organizations who do not come under the jurisdiction of the Commission or which are of administrative nature, the report said.
India News: AGRA: With no improvement in condition for two weeks now, the 19-year-old rape survivor from UP’s Hathras was moved to Delhi’s Safdarjung Hospital fro.
Experts say Covid-19 lockdown has reduced pollutants before stubble burning, so AQI is likely to be lower than last year. But a sharp spike is still expected.
Mumbai: BKC cyber police arrested a fitness trainer from Delhi and brought him here on Monday for posting a video abusing and using filthy language to.
The number of air traffic movements will be limited to 96 — 48 arrivals and departures each per day. The number will increase to 180 by the end of October.
With the legislative session coming to an end, lobbying for ministerial berths has resumed, and Chief Minister BS Yediyurappa appears ready to rejig his cabinet.
AGRA: With no improvement in condition for two weeks now, the 19-year-old rape survivor from Hathras was moved to Delhi’s Safdarjung Hospital from Ali.
The board, which comes under the Delhi government's Labour Department, expressed hesitation over the proposal but the HC said on July 30 and August 26 that it was issuing a direction, not just a suggestion, which the board must implement.
The city government had directed schools to not hike fees till schools remain closed due to COVID-19 and also not levy any charges in the name of development fees or annual fees.
In July, a phase III trial study conducted by Swiss biotech firm Roche suggested that the drug “did not demonstrate a benefit for patients in either clinical status or mortality”.
